Andra AP fonden Buys New Shares in The Cooper Companies, Inc. (NASDAQ:COO)

Andra AP fonden bought a new stake in The Cooper Companies, Inc. (NASDAQ:COO) in the 4th quarter, Holdings Channel.com reports. The fund bought 11,200 shares of the medical device company’s stock, valued at approximately $1,030,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Callan Family Office LLC purchased a new stake in Cooper Companies during the fourth quarter valued at about $381,000. E Fund Management Co. Ltd. grew its position in Cooper Companies by 98.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 3,791 shares of the medical device company’s stock valued at $349,000 after acquiring an additional 1,878 shares during the period. Raymond James Financial Inc. purchased a new stake in Cooper Companies during the fourth quarter valued at about $64,826,000. Arizona State Retirement System grew its position in Cooper Companies by 1.3% during the fourth quarter. Arizona State Retirement System now owns 57,817 shares of the medical device company’s stock valued at $5,315,000 after acquiring an additional 769 shares during the period. Finally, Proficio Capital Partners LLC purchased a new stake in Cooper Companies during the fourth quarter valued at about $95,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Trading Down 6.6 %

NASDAQ:COO opened at $85.00 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The Cooper Companies, Inc. has a one year low of $82.61 and a one year high of $112.38. The business’s 50-day simple moving average is $92.38 and its 200 day simple moving average is $99.44. The stock has a market cap of $16.96 billion, a price-to-earnings ratio of 43.59, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. As a group, sell-side analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on COO shares. Morgan Stanley lowered their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research report on Friday, December 6th. Robert W. Baird lowered their price target on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research report on Friday. Wells Fargo & Company boosted their price target on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. JPMorgan Chase & Co. decreased their target price on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday. Finally, StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $111.89.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.